Mihály Hajós

Mihály Hajós

Auto-generated profile, based on publicly available information

Mihály Hajós

Yale University School of Medicine, New Haven, CT, USA; Cognito Therapeutics, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Neurobiology of Aging
Verified
Journal Article
Closed access
Claudio BabiloniClaudio Babiloni
Claudio Babiloni
KBKatarzyna Blinowska
Katarzyna Blinowska
Laura BonanniLaura Bonanni
Laura Bonanni
ACAndrej Cichocki
Andrej Cichocki
WHWillem De Haan
Willem De Haan
FRFiona Randall
Fiona Randall

10 June 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DWDonn G. Wishka
Donn G. Wishka
DWDaniel Walker
Daniel Walker
KYKaren M. Yates
Karen M. Yates
SRSteven C. Reitz
Steven C. Reitz
SJShaojuan Jia
Shaojuan Jia
BRBruce N. Rogers
Bruce N. Rogers

24 September 2021 in Frontiers in Systems Neuroscience
Verified
Journal Article
Open access
ACAylin Cimenser
Aylin Cimenser
EHEvan Hempel
Evan Hempel
TTTaylor Travers
Taylor Travers
NSNathan Strozewski
Nathan Strozewski
KMKaren Martin
Karen Martin
MHMihály Hajós
Mihály Hajós
Pathological proteins contributing to Alzheimer’s disease (AD) are known to disrupt normal neuronal functions in the brain, leading to unbalanced neuronal excitatory-inhibitory tone, distorted neuronal synchrony, and network oscillations. However, it has been proposed that abnormalities in neuronal activity directly contribute to the pathogenesis of the disease, and in fact it has been demonstrated that induction of synchronized 40 Hz gamma oscillation of neuronal networks by sensory stimulation reverses AD-related pathological markers in transgenic mice carrying AD-related human pathological genes. Based on these findings, the current study evaluated whether non-invasive sensory stimulation inducing cortical 40 Hz gamma oscillation is clinically beneficial for AD patients. Patients with mild to moderate AD (n = 22) were randomized to active treatment group (n = 14; gamma sensory stimulation therapy) or to sham group (n = 8). Participants in the active treatment group received precisely timed, 40 Hz visual and auditory stimulations during eye-closed condition to induce cortical 40 Hz steady-state oscillations in 1-h daily sessions over a 6-month period. Participants in the sham group were exposed to similar sensory stimulation designed to not evoke cortical 40 Hz steady-state oscillations that are observed in the active treatment patients. During the trial, nighttime activities of the patients were monitored with continuous actigraphy recordings, and their functional abilities were measured by Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL) scale. Results of this study demonstrated that 1-h daily therapy was well tolerated throughout the 6-month treatment period by all subjects. Patients receiving gamma sensory stimulation showed significantly reduced nighttime active periods, in contrast, to deterioration in sleep quality in sham group patients. Patients in the sham group also showed the expected, significant decline in ADCS-ADL scores, whereas patients in the gamma sensory stimulation group fully maintained their functional abilities over the 6-month period. These findings confirm the safe application of 40 Hz sensory stimulation in AD patients and demonstrate a high adherence to daily treatment. Furthermore, this is the first time that beneficial clinical effects of the therapy are reported, justifying expanded and longer trials to explore additional clinical benefits and disease-modifying properties of gamma sensory stimulation therapy.Clinical Trial Registration:clinicaltrials.gov, identifier: NCT03556280.

1 June 2019 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
MSMilan Stoiljkovic
Milan Stoiljkovic
CKCraig Kelley
Craig Kelley
BSBernardo Stutz
Bernardo Stutz
THTamas Horvath
Tamas Horvath
MHMihály Hajós
Mihály Hajós
Current findings suggest that accumulation of amyloid-β (Aβ) and hyperphosphorylated tau in the brain disrupt synaptic function in hippocampal–cortical neuronal networks leading to impairment in cognitive and affective functions in Alzheimer’s disease (AD). Development of new disease-modifying AD drugs are challenging due to the lack of predictive animal models and efficacy assays. In the present study we recorded neural activity in TgF344-AD rats, a transgenic model with a full array of AD pathological features, including age-dependent Aβ accumulation, tauopathy, neuronal loss, and cognitive impairments. Under urethane anesthesia, TgF344-AD rats showed significant age-dependent decline in brainstem-elicited hippocampal theta oscillation and decreased theta-phase gamma-amplitude coupling comparing to their age-matched wild-type counterparts. In freely-behaving condition, the power of hippocampal theta oscillation and gamma power during sharp-wave ripples were significantly lower in TgF344-AD rats. Additionally, these rats showed impaired coherence in both intercortical and hippocampal–cortical network dynamics, and increased incidence of paroxysmal high-voltage spindles, which occur during awake, behaviorally quiescent state. TgF344-AD rats demonstrated impairments in sensory processing, having diminished auditory gating and 40-Hz auditory evoked steady-state response. The observed differences in neurophysiological activities in TgF344-AD rats, which mirror several abnormalities described in AD patients, may be used as promising markers to monitor disease-modifying therapies.

1 July 2021 in Ageing Research Reviews
Verified
Journal Article
Closed access
MSMilan Stoiljkovic
Milan Stoiljkovic
THTamas L. Horvath
Tamas L. Horvath
MHMihály Hajós
Mihály Hajós

6 March 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
MHMihály Hajós
Mihály Hajós
ABAlyssa Boasso
Alyssa Boasso
EHEvan Hempel
Evan Hempel
MSMonika Shpokayte
Monika Shpokayte
AKAlex Konisky
Alex Konisky
ZMZach Malchano
Zach Malchano
Background: Alzheimer’s Disease (AD) is a multifactorial, progressive neurodegenerative disease that disrupts synaptic and neuronal activity and network oscillations. It is characterized by neuronal loss, brain atrophy and a decline in cognitive and functional abilities. Cognito’s Evoked Gamma Therapy System provides an innovative approach for AD by inducing EEG-verified gamma oscillations through sensory stimulation. Prior research has shown promising disease-modifying effects in experimental AD models. The present study (NCT03556280: OVERTURE) evaluated the feasibly, safety and efficacy of evoked gamma oscillation treatment using Cognito’s medical device (CogTx-001) in participants with mild to moderate AD.Methods: The present study was a randomized, double blind, sham-controlled, 6-months clinical trial in participants with mild to moderate AD. The trial enrolled 76 participants, aged 50 or older, who met the clinical criteria for AD with baseline MMSE scores between 14 and 26. Participants were randomly assigned 2:1 to receive self-administered daily, one-hour, therapy, evoking EEG-verified gamma oscillations or sham treatment. The CogTx-001 device was use at home with the help of a care partner, over 6 months. The primary outcome measures were safety, evaluated by physical and neurological exams and monthly assessments of adverse events (AEs) and MRI, and tolerability, measured by device use. Although the trial was not statistically powered to evaluate potential efficacy outcomes, primary and secondary clinical outcome measures included several cognitive and functional endpoints.Results: Total AEs were similar between groups, there were no unexpected serious treatment related AEs, and no serious treatment-emergent AEs that led to study discontinuation. MRI did not show Amyloid-Related Imaging Abnormalities (ARIA) in any study participant. High adherence rates (85–90%) were observed in sham and treatment participants. There was no statistical separation between active and sham arm participants in primary outcome measure of MADCOMS or secondary outcome measure of CDR-SB or ADAS-Cog14. However, some secondary outcome measures including ADCS-ADL, MMSE, and MRI whole brain volume demonstrated reduced progression in active compared to sham treated participants, that achieved nominal significance.Conclusion: Our results demonstrate that 1-h daily treatment with Cognito’s Evoked Gamma Therapy System (CogTx-001) was safe and well-tolerated and demonstrated potential clinical benefits in mild to moderate AD.Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT03556280.